To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.


Already Have an Account?

Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:271 Issue:1 Number:1 ISSN#:2564-2537
ACE Report #14814
Ace Report Cover Peri-Operative

Imrecoxib vs. Celecoxib for Pain Control After Arthroscopic Knee Surgery

How to Cite

OrthoEvidence. Imrecoxib vs. Celecoxib for Pain Control After Arthroscopic Knee Surgery. ACE Report. 2022;271(1):1. Available from:

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Imrecoxib versus celecoxib as postoperative analgesia for patients receiving arthroscopic knee surgery: a randomized, controlled, non-inferiority study

Inflammopharmacology. 2022 Jun;30(3): 875-881.

Contributing Authors:
W Guo Y Liu J Li

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


One hundred and twenty-six patients undergoing arthroscopic knee surgery were randomized in this non-inferiority trial to receive either imrecoxib (n=64) or celecoxib (n=62). The primary outcome of interest pain scores on a Visual Analog Scale (VAS), measured at rest and during movement up to 72 hours post-operation. Secondary outcomes of interest included pethidine administration, patient satisfa...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.